Addressing the Realities of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
How is
IGC Pharma
fighting agitation?
We’re advancing IGC‑AD1, a cannabinoid‑based investigational therapy in a double‑blind Phase 2 trial (CALMA), designed to safely reduce agitation and improve quality of life.
Addressing the Realities of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
How is
IGC Pharma
fighting agitation?
We’re advancing IGC‑AD1, a cannabinoid‑based investigational therapy in a double‑blind Phase 2 trial (CALMA), designed to safely reduce agitation and improve quality of life.
What is CALMA?
We’re advancing IGC‑AD1, a cannabinoid‑based investigational therapy in a double‑blind Phase 2 trial (CALMA), designed to safely reduce agitation and improve quality of life.
Explore CALMA →What is IGC-AD1?
IGC‑AD1 is our lead candidate—a partial CB1 receptor agonist with anti‑inflammatory action, designed to relieve agitation in Alzheimer’s dementia.
Learn About IGC‑AD1 →What is MINT-AD?
MINT‑AD is our AI‑powered platform that uses speech and behavioral biomarkers for early Alzheimer’s detection and better trial outcomes.
Discover MINT‑AD →